BACKGROUND - We investigated whether age influences the predictiveness of genetic risk score (GRS) for prostate cancer (PCa) in a Chinese hospital-based biopsy cohort.
METHODS - We included consecutive patients who underwent prostate biopsies in two tertiary centers between 2012 and 2014. GRS was calculated using 24 PCa-associated genetic variants and its predictiveness was assessed by area under curve (AUC).
RESULTS - Of 1120 men tested, 724 with prostate-specific antigen (PSA) < 20 ng/ml were selected for further analysis. Patients were divided into 3 groups by age cutoffs at 60 and 70 years. GRS significantly predicted PCa for all patients (AUC: 0.561; 95% CI: 0.514-0.609) and was an independent predictor in multivariate analysis for the 60-70 year-olds (AUC: 0.612, 95% CI: 0.541-0.684), but not for patients aged < 60 years or ≥70 years. For PCa with Gleason score ≥7, GRS discriminative ability was 0.582 (95% CI=0.527-0.637) for all patients, and 0.647 (95% CI: 0.541-0.684) for the 60-70 year-old group.
CONCLUSION - GRS significantly increased clinical prediction of PCa and high-grade disease in Chinese men aged 60-70 years, which implies that men in this age group would benefit most from genetic testing.
Oncotarget. 2015 May 15. [Epub ahead of print]
Zhu Y1,2, Han CT1,2, Chen HT3,4,5, Liu F3,4,5, Zhang GM1,2, Yang WY1,2, Xu JF3,4,5,6, Ye DW1,2.
1 Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
2 Department of Oncology, Shanghai Medical Colleague, Fudan University, Shanghai, China.
3 Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China.
4 State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
5 Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, China.
6 Center for Cancer Genomics, Wake Forest School of Medicine, Winston-Salem, NC, USA.